US-based genomics tools developer RainDance Technologies filed for an initial public offering on Friday and will seek to raise up to $60m.
RainDance produces and sells systems, consumables and assays for the ultra-sensitive detection and analysis of complex genetic diseases. It made an $8.8m net loss in 2014 from revenues of $30.6m.
RainDance’s investors include GE Ventures, the corporate venturing subsidiary of conglomerate General Electric which provided $16.5m in series E funding to it in 2013 together with private equity firm Northgate Capital and all its existing backers.
The company has raised more than $100m in venture capital since it was founded in 2004, and neither GE nor Northgate are among its leading shareholders, though biotechnology producer Myriad Genetics is also a past backer.
Mohr Davidow Ventures is RainDance’s largest shareholder, with a 34.4% stake, while other notable backers include Quaker Capital (18.5%), Alloy Ventures (13.3%) and Acadia Woods Partners (8%). Northgate owns a 6.1% share.
BofA Merrill Lynch, Cowen and Company and Evercore ISI are acting as book-running managers for the IPO, which will take place on Nasdaq.